Nonetheless, the therapeutic effect of the tumor-specific CD8 T cell response could be affected by immune checkpoint receptors (i.e., programmed cell death protein 1 (PD-L1) and B and T-lymphocyte attenuator (BTLA) that send inhibitory signals to T cells) (6). The gene discussed is PDCD1; the disease is neoplasm.